Design of oxytocin antagonists, which are more selective than Atosiban

Journal of Peptide Science

Volumn 7, Issue 9, 2001, Pages 449-465

  Manning, Maurice ^a,b   Stoev, Stoytcho ^a   Cheng, Ling Ling ^a   Wo, Nga Ching ^a   Chan, W Y ^a  

^a MEDICAL COLLEGE OF OHIO   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Antagonists; Atosiban; OT receptor; Oxytocin; Selectivity; Tractocile; V1a receptor; Vasopressin

Indexed keywords

ATOSIBAN; MAGNESIUM ION; OXYTOCIN; OXYTOCIN ANTAGONIST; OXYTOCIN RECEPTOR; UTERUS SPASMOLYTIC AGENT; VASOPRESSIN; VASOPRESSIN RECEPTOR ANTAGONIST; VASOPRESSIN V1 RECEPTOR; VASOPRESSIN V2 RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDIURESIS; CONTROLLED STUDY; DRUG ACTIVITY; DRUG APPROVAL; DRUG DESIGN; DRUG DETERMINATION; DRUG POTENCY; DRUG SELECTIVITY; DRUG SYNTHESIS; EUROPE; FEMALE; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PREMATURE LABOR; PRIORITY JOURNAL; RAT; REVIEW;

BIOLOGICAL ASSAY; CHROMATOGRAPHY, THIN LAYER; DRUG DESIGN; HORMONE ANTAGONISTS; METHYLTYROSINES; OXYTOCIN; PEPTIDE BIOSYNTHESIS; PEPTIDES; RECEPTORS, VASOPRESSIN; VASOPRESSINS; VASOTOCIN;

EID: 0034807296     PISSN: 10752617     EISSN: None     Source Type: Journal    
DOI: 10.1002/psc.339     Document Type: Review

References (109)

1. The contribution of low birth weight to infant mortality and morbidity
2. The continuing challenge of preterm delivery
3. Preterm birth prevention: Where we are?
4. Stopping premature births before it's too late
5. The control of labor
6. Endocrine and paracrine regulation of birth at term and preterm
7. Endocrinology of parturition
8. Oxytocin receptors: Triggers for parturition and lactation?
9. Oxytocin receptors and human parturition: A dual role for oxytocin in the initiation of labor
10. Oxytocin receptor blockade: A new principle in the treatment of preterm labor?
11. Myometrial oxytocin receptors and prostaglandin in the parturition process in the rat
12. Oxytocin gene expression in rat uterus
13. Oxytocin antagonists delay the initiation of parturition and prolong its active phase in rats
14. Inhibition of the uterus-contracting effect of oxytocin by O-methyl oxytocin
15. Synthesis of 1-L-penicillamine-oxytocin, 1-D-penicillamine-oxytocin and 1-deaminopenicillamine-oxytocin, potent inhibitors of the oxytocic response of oxytocin
16. Synthesis of three oxytocin analogs related to [1-deaminopenicillamine]-oxytocin possessing antioxytocic activity
17. Some pharmacological properties of a synthetic oxytocin analogue 1-N-carbamoyl-hemicystine-2-O-methyltyrosine (carbamoyl-methyloxytocin), an antagonist to the neurohypophysial hormones
18. Synthesis of new oxytocin analogs modified in the 2-position
19. [1-β-mercapto-β,β-pentamethylenepropionic acid]oxytocin, a potent inhibitor of oxytocin
20. [1-Deaminopenicillamine, 4-threonine]-oxytocin, a potent inhibitor of oxytocin
21. Synthetic antagonists of in vivo responses by the rat uterus to oxytocin
22. The design of effective in vivo antagonists of rat uterus and milk ejection response to oxytocin
23. Design and synthesis of potent in vivo antagonists of oxytocin
24. Synthesis, pharmacological, conformational, and dynamic studies of the potent hormone antagonists [1-penicillamine, 4-threonine]-oxytocin
25. Oxytocin analogues with inhibitory properties, containing in position 2 a hydrophobic amino acid of D-configuration
26. Design of oxytocin antagonists with prolonged action: Potential tocolytic agents for the treatment of preterm labor
27. Synthetic antagonists of the myometrial response to vasopressin and oxytocin
28. Long-acting oxytocin antagonists: Effects of 2-D-stereoisomerism substitution on antagonistic potency and duration of action
29. Synthesis and some pharmacological properties of 2 new antagonists of oxytocin
30. 9]OVT: A selective oxytocin receptor ligand
31. Solid phase synthesis of sixteen potent (selective and nonselective) in vivo antagonists of oxytocin
32. Synthesis and biological-activity of oxytocin analogs with beta-amino acids in position-2
33. A new tocolytic agent: Development of an oxytocin antagonist for inhibiting uterine contractions
34. Some pharmacological properties of cyclic and linear analogs obtained by substituting each residue of an oxytocin antagonist with D-tryptophan
35. Design of potent oxytocin antagonists featuring D-tryptophan at position 2
36. Improvement in potency of an oxytocin antagonist after systematic substitutions with L-tryptophan
37. Structure-activity studies of a novel bicyclic oxytocin antagonist
38. Analogs of deamino carba oxytocin with inhibitory properties-synthesis and biological-activities
39. Synthesis and properties of hormonogen and inhibitorogen type oxytocin analogs
40. Conformationally biased analogs of oxytocin
41. 6-substituted analogue
42. 1-(((7,7-Dimethyl-2(S)-(2(S)-amino-4-(methylsulfonyl) butyramido) bicyclo[2.2.1]-heptan-1(S)-yl)methyl)sulfonyl)-4-(2 -methylphenyl)piperazine (L-368,899): An orally bioavailable, non-peptide utility for managing pre-term labor
43. Antagonistic analogs of oxytocin with substituted phenylalanine or tyrosine in position 2
44. Synthesis of methylated phenylalanines via hydrogenolysis of corresponding 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids. Synthesis and biological activity of oxytocin analogs with methylated phenylalanines in position 2
45. Enhanced selectivity of oxytocin antagonists containing sarcosine in position-7
46. The 1- and 2-naphthylalanine analogs of oxytocin and vasopressin
47. 6 interchange in selective and non-selective antagonists of vasopressin and oxytocin
48. Design and synthesis of highly selective in vitro and in vivo uterine receptor antagonists of oxytocin: Comparisons with Atosiban
49. 1a receptor antagonists. New approaches for the design of potential tocolytics for preterm labor
50. 1-(1-[4-[N-acetyl - 4 - piperidinyl]oxy] - 2 -methoxybenzoyl]piperidin - 4 -yl)-4H-3,1-benzoxazin-2(1H)-one (L-371,257): A new, orally bioavailable, non-peptide oxytocin antagonist
51. Substitution of the side-chain-constrained amino acids beta-methyl-2′, 6-dimethyl-4′-methoxytyrosine in position 2 of a bicyclic oxytocin analogue provides unique insights into the bioactive topography of oxytocin antagonists
52. The synthesis of new class of oxytocin antagonists
53. The analogs of oxytocin and D-homoarginine vasopressin with bulky substituted phenylalanine in position 2
54. Analogues of arginine vasopressin modified in position 2 or 3 with naphthylalanine: Selective antagonists of oxytocin in-vitro
55. Structure-activity relationships of neurohypophyseal peptides
56. Analogs with inhibitory properties
57. Discovery, development and some uses of vasopressin and oxytocin antagonists
58. Design, synthesis and some uses of receptor specific agonists and antagonists of vasopressin and oxytocin
59. Advances in the design of selective antagonists, potential tocolytics and radioiodinated ligands for oxytocin receptors
60. Small molecule ligands for oxytocin and vasopressin receptors
61. Oxytocin receptor antagonists update
62. Receptor for and myometrial responses to oxytocin and vasopressin in preterm and term human pregnancy: Effects of the oxytocin antagonist Atosiban
63. The effect of the oxytocin antagonist Atosiban on preterm uterine activity in the human
64. The physiological basis for administration of oxytocin antagonists in preterm labour
65. Dose ranging study of the oxytocin antagonist Atosiban in the treatment of preterm labor
66. The treatment of preterm labor with the oxytocin antagonist Atosiban
67. An oxytocin receptor antagonist (Atosiban) in the treatment of preterm labor: A randomised, double-blind, placebo-controlled trial with tocolytic rescue
68. Maintenance treatment of preterm labor with the oxytocin antagonist Atosiban
69. Double-blind, randomized, controlled trial of Atosiban and ritodrine in the treatment of preterm labor: A multicenter effectiveness and safety study
70. Inhibition of premature labor in sheep by a combined treatment of nimesulide, a prostaglandin synthase type 2 inhibitor, and Atosiban, an oxytocin receptor antagonist
71. Radioligand binding studies reveal marked species differences in the vasopressin V1 receptor of rat, rhesus and human tissues
72. 1a vasopressin receptors
73. Structural bases of vasopressin/oxytocin receptor function
74. Pharmacologic characterization of the oxytocin receptor in human uterine smooth muscle cells
75. Molecular pharmacology of vasopressin and oxytocin receptors and therapeutic potential
76. 1a receptors in uterine contractions in rats; Implication for tocolytic therapy with oxytocin antagonists
77. Analogs of bradykinin containing β-2-thienyl-L-alanine
78. Agonist and antagonist relationships in 1- and 8-substituted analogs of angiotensin II
79. Synthesis and some pharmacological properties of [3-β-(2-thienyl)-L-alanine]-8-lysine-vasopressin
80. An investigation of position three in arginine vasopressin with aliphatic, aromatic, conformationally restricted, polar and charged amino acids
81. Discovery and design of novel and selective vasopressin and oxytocin agonists and antagonists: The role of bioassays
82. Solid phase synthesis of [deamino-4-valine]-8-D-arginine vasopressin (dVDAVP)
83. Solid phase peptide synthesis. III. An improved synthesis of bradykinin
84. New method for the synthesis of peptides: Activation of the carboxyl group with dicyclohexylcarbodiimide by using 1-hydroxy-benzotriazole as additives
85. Vasopressin antagonists with C-terminal ethylenediamine-linked retro amino acids
86. A method of synthesis of long peptide chains using a synthesis of oxytocin as an example
87. Synthetic metabolites of neurohypophyseal hormones [des-9-glycinamide]oxytocin and [des-9-glycinamide, des-8-leucine]oxytocin
88. 1) receptors
89. Synthesis by the Merrifield method of a protected nonapeptide amide with the amino acid sequence of oxytocin
90. Active esters and resins in peptide synthesis
91. Solid-phase synthesis and pressor potency of [1-deamino-9-ethylenediamine]-lysine-vasopressin
92. A synthetic preparation possessing biological properties associated with arginine-vasopressin
93. The synthesis of oxytocin
94. Trifluoromethanesulfonic acid as a deprotecting reagent in peptide chemistry
95. Acidolytic deprotecting procedures in peptide synthesis
96. A highly potent analogue of oxytocin, desamino-oxytocin
97. Solid phase synthesis of somatostatin and glucagon-selective analogs in gram quantities
98. The purification of synthetic oxytocin and analogues by gel filtration on Sephadex G-15
99. A modification of the method of Dale and Laidlaw for standardization of posterior pituitary extract
100. pA, a new scale of the measurement of drug antagonism
101. [1-β-mercapto-β,β-diethyl-propionic acid]-8-lysine-vasopressin a potent inhibitor of 8-lysine-vasopressin and of oxytocin
102. Effect of magnesium ion on the response of the rat uterus to neurohypophysical hormones and analogues
103. A pharmacologic analysis on the significance of the chemical functional groups of oxytocin to its oxytocic activity and on the effect of magnesium on the in vitro and in vivo oxytocic activity of neurohypophysial hormones
104. The quantitative assay of vasopressin
105. Biologic assays for oxytocin and vasopressin
106. The preparation of Merrifield-resins through total esterification with caesium salts
107. A facile synthesis of β-(S-benzylmercapto)-β,β-cyclopentamethylene-propionic acid
108. Activation of functional oxytocin receptors stimulates cell proliferation in human trophoblast and choriocarcinoma cell lines